Tilray Brands TLRY
NASDAQ TLRY
$4.60 -0.23 (-4.77%)
At close: Aug 20, 2026 · 1:54 PM UTC

Tilray Brands (TLRY) Total Non-Current Liabilities (2019 - 2026)

Tilray Brands' (TLRY) quarterly Total Non-Current Liabilities came in at $728.7 million in Q2 2026, up 27.91% YoY from $569.8 million in Q2 2025, and up 32.75% on a QoQ basis from $549.0 million in Q1 2026.

Tilray Brands (TLRY) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends

Tilray Brands (TLRY) has 8 years of Total Non-Current Liabilities data on file, last reported at $728.7 million in Q2 2026.

  • Quarterly Total Non-Current Liabilities rose 27.91% year-over-year to $728.7 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $728.7 million (up 27.91% YoY) and the FY2026 annual result came in at $728.7 million, up 27.91% from the prior year.
  • Total Non-Current Liabilities climbed to $728.7 million in Q2 2026, from $549.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $1.2 billion in Q1 2022 to a low of $549.0 million in Q1 2026.
  • A 5-year average of $831.5 million and a median of $855.8 million in 2024 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2022 — Total Non-Current Liabilities tumbled 35.52% — and 2026, when it climbed 27.91%.
  • Tracing TLRY's Total Non-Current Liabilities over 5 years: stood at $991.0 million in 2022, then declined by 6.74% to $924.2 million in 2023, then declined by 20.13% to $738.1 million in 2024, then declined by 25.26% to $551.7 million in 2025, then surged by 32.1% to $728.7 million in 2026.
  • The last three Total Non-Current Liabilities figures came in at $728.7 million (Q2 2026), $549.0 million (Q1 2026), and $551.7 million (Q4 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 43.91 Bn 42.95 Bn - -13.28 Bn
2 Teva Pharmaceutical Industries 42.98 Bn 39.32 Bn 2.15 Bn 16.45 Bn
3 Zoetis 31.53 Bn 29.86 Bn 1.05 Bn 11.64 Bn
4 Takeda Pharmaceutical 28.61 Bn 22.81 Bn 5.10 Bn 33.50 Bn
5 United Therapeutics 22.16 Bn 19.49 Bn 683.80 Mn 607.80 Mn
6 Viatris 18.74 Bn 17.85 Bn 1.46 Bn 18.76 Bn
7 Neurocrine Biosciences 15.51 Bn 15.12 Bn 935.80 Mn 1.37 Bn
8 Elanco Animal Health 11.76 Bn 11.23 Bn 798.00 Mn 6.42 Bn
9 Dr Reddys Laboratories 10.12 Bn 9.95 Bn - 334.00 Mn
10 Tilray Brands 513.87 Mn 279.24 Mn 90.52 Mn 728.75 Mn

Historic Data

Download Data
DateValue
May 31, 2026 728.75 Mn
Feb 28, 2026 548.95 Mn
Nov 30, 2025 551.67 Mn
Aug 31, 2025 561.99 Mn
May 31, 2025 569.75 Mn
Nov 30, 2024 738.13 Mn
Aug 31, 2024 778.35 Mn
May 31, 2024 778.40 Mn
Feb 29, 2024 855.82 Mn
Nov 30, 2023 924.20 Mn
Aug 31, 2023 987.69 Mn
May 31, 2023 966.43 Mn
Feb 28, 2023 958.53 Mn
Nov 30, 2022 991.05 Mn
Aug 31, 2022 1.03 Bn
May 31, 2022 1.01 Bn
Feb 28, 2022 1.16 Bn
Nov 30, 2021 1.29 Bn
Aug 31, 2021 1.60 Bn
May 31, 2021 1.56 Bn